Artios

To add a bio or update company history, please click update information.

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

18 Nov 2025

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

Artios Pharma develops cancer treatments that target DNA damage response pathways, focusing on patient groups with limited existing treatment options.

Artios

Life Sciences
Cambridge, United Kingdom
£90m
artios.com
Update Information

More venture news

Apoha
3 Jun 2026
Apoha unlocks £27m in funding led by Singular to measure how molecules and materials behave under real-world conditions
EquityLife Sciences
IMU Biosciences
2 Jun 2026
IMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis
Series ALife Sciences
Perceptic
28 May 2026
Perceptic raises a £9m seed round led by Accel to unify drug discovery and development on a single AI platform
SeedLife Sciences

Artios

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

More venture news

Apoha unlocks £27m in funding led by Singular to measure how molecules and materials behave under real-world conditions

IMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis

Perceptic raises a £9m seed round led by Accel to unify drug discovery and development on a single AI platform